The FDA's Position It must be clearly stated that although requiring the regulatory agency to adjudicate on the clinical safety and efficacy of medical devices before allowing commercial marketing, the Act prohibits interceding in patient care and clinical judgments associated with medical practice, the domain of the peer review and staff accreditation process. 6 The FDA requires that clinical data submitted in support of a PMA application meet a standard of scientific evidence acceptable for peer review. A panel of clinical experts in the field of the device's application will examine the scientific submission in support of the PMA application and, on the basis of that evidence, make its recommendation to the FDA regarding marketing approval. The Advisory Panel has usually requested a clinical trial, randomized for control of bias, to generate this evidence.
PMA Protocols
Performance of the clinical study requires application to the FDA for an investigational device exemption (IDE) to permit clinical use of an unapproved device. The proposed study must also be approved by the local institutional review board.
The agency provides information in draft guidance documents outlining the type of information generally required to demonstrate device safety and efficacy and the acceptable study designs to generate this data for PMA applications. These documents are supplemented with iterative consultations with sponsors and investigators. However, it is the responsibility of the sponsor to develop and submit an appropriate study protocol. It should be emphasized that the investigators, with their clinical and scientific background, must assume intellectual responsibility for participating in and advising the sponsors on the design of any protocol in which they will be involved in executing.
An initial pilot (feasibility) study may be recommended or required to define the end points and refine methodology for the definitive clinical study.
The regulations for premarket clinical device testing were adapted from those for the drug model. However, provision is made for peculiarities associated with device testing. Examples of these are the difficulties in implementing blinded studies, the ethical constraints on "sham" procedures to provide placebo controls, and the difficulties inherent in using approved devices as active controls. Recognizing these differences, the agency has therefore readily considered alternatives to a randomized active concurrent control for study design when provided with clinical and statistical justification. This flexibility was evident at recent workshops sponsored by the Center for Devices and Radiological Health to discuss the role and improve the general quality of clinical trials in device evaluation. Comments 
Prosthetic Cardiac Valves and Interventional Cardiology Devices
The progress achieved over the past 30 years in the development and design of prosthetic cardiac valves has resulted in an extremely low complication rate over the short term. As a consequence, the magnitude of a randomized controlled clinical trial to evaluate any new prosthetic heart valve and provide statistically meaningful data acquires proportions beyond what can be reasonably achieved with the relatively low incidence of prosthetic valve replacement. Thus, the guidance document for valve prostheses has accepted the concept of an observational study protocol design with data analysis based on patient risk-related objective performance criteria developed from historical data. Preliminary in vitro and in vivo studies become even more important with this study design, and an initial clinical pilot study may be required. The SMDA of 1990, in providing for required and discretionary postmarketing surveillance studies with device-tracking requirements, enables the monitoring of and prompt response to chronic device performance.
The draft guidance document relating to interventional cardiology devices illustrates situations where randomized controlled clinical trials are essential to establish safety and efficacy. Because treatment benefit for many of these devices is dependent on subjective assessments, concurrent randomization of the controls is essential. The potential for selection and assessment bias is also considerable, and increasing importance is therefore being placed on blinded core laboratory analysis of assessment data, such as angiograms. In the case of devices that are insignificant configuration modifications to approved devices, such as angioplasty catheters with minor changes in balloon length, these requirements could reasonably be relaxed. Once a PMA is approved, new indications for a device may become apparent when use is generalized to the target population. Appropriate labeling changes to accommodate these indications can then be sought with a PMA amendment based on valid scientific evidence.
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